This poster is absolutely bonkers & I LOVE it Huge table. Frequency of everything over time Really interesting to see which activity persists / how much damage is accumulated Every trial should be obligated to share this (esp SLE!) #ACR25 @RheumNow #ACRBest Abst#1608 https://t.co/blRrvwi3qP

Mease et al. What agent to use after failure of first TNFi in PsA. Real world study, 320 patients. Switching to upadacitinib led to better joint responses than second TNFi or IL17i @RheumNow #ACR25 Abstr#1453 https://t.co/SQnN0skw7r

Interim analysis of Ph3 TULIP-SC trial: Anifrolumab 120mg SC or PBO weekly + SOC x 52wks Primary endpt met: BICLA response w/Anifrolumab (60.3%) vs. PBO(43.9%)[p=0.014] Pts on Ani had sustained BICLA response upto wk 52 (HR 2.1) Promising results. #ACR25 @RheumNow Abs1545 https://t.co/nqse1BiGq2

What can we use to better predict MACE in RA patients? ESPOIR cohort showed value of two cardiac biomarkers: - hs-cTnT - soluble ST2 Combined, predicted MACE even after adjusting for disease activity/traditional CV RF. We need something like this! #ACR25 ABST1334 @RheumNow https://t.co/EUNDuuMaYD

Loarce et al. Poor performance of CXR and PFT in diagnosing RA-ILD (compared to HRCT). Message is, if you think they have RA-ILD, you need to do CT. @RheumNow #ACR25 Abstr#1335 https://t.co/eeSTf72mvM

Fragoulis et al. Real world study of bimekizumab demonstrates equal efficacy in IL-17i naive and exposed. @RheumNow #ACR25 Abstr#1439 https://t.co/aCcLgnKvFJ

Gensler et al. Bimekizumab in male and female axSpA patients. Greater benefit in males at week 16, but similar responses at week 52 @RheumNow #ACR25 Abstr#1449 https://t.co/zDYI2zItqT

Getting RA patients into remission: have we plateaued? @MayoClinic data: early and later into the biologic era, and still median time to RA remission is >3y Surely we can aspire to more? Let’s target barriers to implementing better #ACR25 @ElHasbaniG @MyasoedovaElena @RheumNow https://t.co/JLTuL5cIet

Mac Gearailt et al. Depression in axSpA. Depression in 10%. Associated higher disease activity, worse functional status, and increased peripheral manifestations. @RheumNow #ACR25 Abstr#1409 https://t.co/8pnoQiaiQr

Kharouf et al. Effect of handedness on radiographic damage in PsA. Left-handedness associated increased peripheral damage, especially in left hand. Hypothesis that having to use tools designed for right-handedness increases mechanical stress @RheumNow #ACR25 Abstr#1415 https://t.co/gfGQkrYyc8